[HTML][HTML] Advances in the development of new biomarkers for Alzheimer's disease
TO Klyucherev, P Olszewski, AA Shalimova… - Translational …, 2022 - Springer
Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
Advances in the development of new biomarkers for Alzheimer's disease.
TO Klyucherev, P Olszewski, AA Shalimova… - Translational …, 2022 - europepmc.org
Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
[PDF][PDF] Advances in the development of new biomarkers for Alzheimer's disease
TO Klyucherev, P Olszewski, AA Shalimova… - 2022 - academia.edu
Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
Advances in the development of new biomarkers for Alzheimer's disease.
TO Klyucherev, P Olszewski… - Translational …, 2022 - search.ebscohost.com
Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
[HTML][HTML] Advances in the development of new biomarkers for Alzheimer's disease
TO Klyucherev, P Olszewski… - Translational …, 2022 - translationalneurodegeneration …
Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
[引用][C] Advances in the development of new biomarkers for Alzheimer's disease
TO Klyucherev, P Olszewski, AA Shalimova… - Translational …, 2022 - elibrary.ru
[HTML][HTML] Advances in the development of new biomarkers for Alzheimer's disease
TO Klyucherev, P Olszewski… - Translational …, 2022 - ncbi.nlm.nih.gov
Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
Advances in the development of new biomarkers for Alzheimer's disease
TO Klyucherev, PK Olszewski, A Shalimova… - Translational …, 2022 - diva-portal.org
Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
Advances in the development of new biomarkers for Alzheimer's disease
TO Klyucherev, P Olszewski… - Translational …, 2022 - pubmed.ncbi.nlm.nih.gov
Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
Advances in the development of new biomarkers for Alzheimer's disease
TO Klyucherev, P Olszewski… - Translational …, 2022 - search.proquest.com
Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …